Recombinant erythropoietin (EPO) and darbepoetin (DARBO) are the first-line agents used for treating anemia in LR MDS patients who have serum EPO (sEPO) levels ≤ 500 U/L. This evidence concerns the gene EPO and myelodysplastic syndrome.